A phase 1 pharmacokinetic bioequivalence study of DMB-3113 and adalimumab in healthy Japanese adult male subjects
Phase of Trial: Phase I
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Meiji Seika Pharma
- 17 Aug 2017 Status changed from active, no longer recruiting to completed.
- 23 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Oct 2016 New trial record